Caina Technology (301122.SZ) plans to acquire 70% of Jiangxi Fenglin's equity for 21 million yuan.

Caina Technology (301122.SZ) announced that the company plans to acquire 70% of the equity of Jiangxi Fenglin Medical Technology Co., Ltd. (referred to as "Jiangxi Fenglin") held by Xue Lifan for a total of 21 million yuan. After the completion of this transaction, Jiangxi Fenglin will become a subsidiary of the company and will be included in the company's consolidated financial statements. The company's main product sales are mainly for export, with customers mostly being well-known medical and veterinary product companies in Europe and America. Jiangxi Fenglin mainly engages in the production and sales of medical devices in China, and has a stable marketing team and market channels in some provinces and regions in the country, as well as a complete and mature sales system for domestic medical devices. The main products have obtained domestic medical device registration certificates. By acquiring 70% of the equity of Jiangxi Fenglin, the company aims to make it a subsidiary and, essentially, to quickly address the company's weaknesses in the domestic market and expand its strategic space through "external integration".